Measles Vaccine, Live Attenuated
Indications
Registered South African indications:
- Immunisation against measles
Cautions
Contraindications
- Hypersensitivity to the active ingredient or any of the excipients
- Active or developing acute respiratory infection, including active untreated tuberculosis
- Acute infectious diseases, leukaemia, severe anaemia, and other severe diseases of the blood system
- Severe impairment of renal function and decompensated heart diseases
- Measles vaccine should be avoided in other cell-mediated immune deficiency states
- Known allergy to kanamycin sulphate and erythromycin
Measles vaccine may be used in children with known or suspected HIV infection, as there is no evidence to date of any increased rate of adverse reactions in symptomatic or asymptomatic HIV-infected children
Cautions
- Pregnancy
- Breastfeeding
- Mild to moderate renal impairment
- Thrombocytopenia
- History of idiopathic thrombocytopenia purpura
- Bleeding disorder
Adult dosage
Not established for use in adults
Paediatric dosage
Forms avail. in SA and covered in this monograph: inj
Immunisation of children at 9-18 months of age
- SC: 0.5ml
Not to be used in combination with other childhood vaccinations
DO NOT administer via IV or IM route
Special populations
Pregnancy
- Caution; not recommended
Breastfeeding
- Caution; not recommended
- There is limited experience with the Measles vaccine during breastfeeding
- Studies have shown that breastfeeding postpartum women vaccinated with live attenuated rubella vaccines may secrete the virus in breast milk and transmit it to breastfed infants without evidence of any symptomatic disease
- Only in the event the child is confirmed or suspected to be immunodeficient, risks and benefits of vaccinating the mother should be evaluated
Renal Impairment
- Mild to moderate: Caution; no information available
- Severe: Contraindicated
Hepatic Impairment
- No dose adjustment recommended
Elderly
- Not indicated for use in geriatric patients
Porphyria Information
Drugs in Sport
- Permitted - No warnings
Adverse reactions
Central Nervous System Disorders
- Febrile convulsion
Gastrointestinal Disorders
- Diarrhoea
- Nausea and vomiting
- Abdominal pain
Immune, Blood and Lymphatic System Disorders
- Adenopathy
- Thrombocytopaenic purpura
- Allergic reaction
- Anaphylactic reaction
- Anaphylactoid reactions
Sensory Disorders
- Conjunctivitis
Interactions
- Immunoglobulins
- Immunosuppressants
- Corticosteroids
Monitoring
None routine
Mechanism of action
The live, attenuated measles vaccine stimulates the production of antibodies to the measles virus.
Dosage forms
- Injection
- Vaccine
Formulation
Injection 0.5ml
- Rouvax (Sanofi) originator
- Measbio (Biovac)
- Measles Vaccine Cipla (Cipla Medpro)
References
1. SAMF_12th Edition_Page 363 2. https://drive.google.com/drive/folders/14DoIooPuWgpJn_50PPNPmCbKyBW8jtT0 (04/2014_Sanofi_Rouvax) 3. https://drive.google.com/drive/folders/14DoIooPuWgpJn_50PPNPmCbKyBW8jtT0 (30/10/2016_Biovac_MeasBio) 4. SmPC: Priorix (GlaxoSmithKline UK) , Last updated on emc: 14 Jan 2020 , Downloaded 11/3/2020 [https://www.medicines.org.uk/emc/product/1159] 5.Clinical Pharmacologist - Dr. M Irhuma [https://trello.com/c/rMS5bjHg/321-list-of-hot-monographs] 6. http://porphyriadrugs.com/ (NAPOS) [Accessed on 18/2/2020] 7. PI - MeasBio (freeze-dried powder for reconstitution and injection), The Biovac Institute - Date of most recent revision: 13 July 2021 - Downloaded online 03 October 2024 [https://pi-pil-repository.sahpra.org.za/wp-content/uploads/2023/03/Measbio-Approved-pi-20-Oct-2021.pdf]
Brands & products
4 products · cached snapshot- Rouvax
- MeasBio
- Measles Vaccine Cipla
INJInjection· 3 products
from R157.05| Product | Strength | Pack | Applicant | Min price |
|---|---|---|---|---|
| Measles Vaccine Cipla | 1000 ccid50/0.5ml | 1 | Cipla Medpro (Pty) Ltd | R157.05 |
| Measles Vaccine Cipla | 1000 ccid50/0.5ml | 1 | Cipla Medpro (Pty) Ltd | R1570.58 |
| Measbio | 1000 ccid50/0.5ml | 5 | The Biovac Institute | R1924.04 |
VACVaccine· 1 product
from R195.72| Product | Strength | Pack | Applicant | Min price |
|---|---|---|---|---|
| Rouvax | 1000 tcid50/0.5ml | 0.5 | Sanofi Aventis South Africa (Pty) Ltd | R195.72 |
Medical aid coverage
data not yet integrated- Comprehensive Series—
- Executive Plan—
- KeyCare Series—
- Priority Series—
- Saver Series—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- BonClassic—
- BonComprehensive—
- BonEssential—
- BonFit Select—
- BonSave—
- BonStart—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- Beryl—
- Emerald—
- Onyx—
- Ruby—
- Sapphire—
- Tanzanite One—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- Aquarium Option—
- Efficiency Option—
- Marine Option—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.